Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...
Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...
Glenview, Illinois – On World Bronchiectasis Day (July 1), the American College of Chest Physicians (CHEST) is announcing the launch of Bridging Specialties ®: Timely Diagnosis for NTM Disease and ...
Nebulized tobramycin significantly reduced the density of Pseudomonas aeruginosa in sputum and improved quality of life for adults with bronchiectasis in a study with more than 300 individuals.
Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...
Mark Metersky, MD, FCCP, illustrates the pathology of bronchiectasis. This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on bronchiectasis. Bronchiectasis is an ...
Please provide your email address to receive an email when new articles are posted on . Indigenous ethnicity and new abnormal auscultatory signs raised the odds for symptom resolution after antibiotic ...
Non–cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory condition of the lungs associated with respiratory infections and daily cough and sputum. Non-cystic fibrosis bronchiectasis. Image ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results